Targeting Akt3 Signaling in Triple-Negative Breast Cancer

Y. Rebecca Chin¹, Taku Yoshida²,³, Andriy Marusyk²,³, Andrew H. Beck¹, Kornelia Polyak²,³,⁴, and Alex Toker¹

Abstract

Triple-negative breast cancer (TNBC) is currently the only major breast tumor subtype without effective targeted therapy and, as a consequence, in general has a poor outcome. To identify new therapeutic targets in TNBC, we performed a short hairpin RNA (shRNA) screen for protein kinases commonly amplified and overexpressed in breast cancer. Using this approach, we identified Akt3 as a gene preferentially required for the growth of TNBCs. Downregulation of Akt3 significantly inhibits the growth of TNBC lines in three-dimensional (3D) spheroid cultures and in mouse xenograft models, whereas loss of Akt1 or Akt2 have more modest effects. Akt3 silencing markedly upregulates the p27 cell-cycle inhibitor and this is critical for the ability of Akt3 to inhibit spheroid growth. In contrast with Akt1, Akt3 silencing results in only a minor enhancement of migration and does not promote invasion. Depletion of Akt3 in TNBC sensitizes cells to the pan-Akt inhibitor GSK690693. These results imply that Akt3 has a specific function in TNBCs; thus, its therapeutic targeting may provide a new treatment option for this tumor subtype. Cancer Res; 74(3): 964–73. ©2013 AACR.

Introduction

Breast cancer is the most common cancer among women worldwide. On the basis of the gene expression profiling, this disease is categorized into three major subtypes: luminal, HER2+/estrogen receptor–negative (ER−), and basal-like (1). Recent developments in endocrine therapy for the treatment of luminal breast cancer and Her2 targeted therapy, such as trastuzumab for HER2+/ER− tumors, have led to improved survival for a subset of patients with breast cancer (2–4). However, the basal-like subtype, which comprises approximately 15% of invasive breast cancers and is generally triple-negative [ER−, progesterone receptor–negative (PR−), and HER2−], lacks targeted therapy (5, 6). Currently, chemotherapy is the only option for the treatment of triple-negative breast cancers (TNBC), but its clinical benefit is limited to a subset of patients. Because of poor prognosis and a more aggressive phenotype, there is an urgent clinical need to identify novel therapeutic targets for TNBCs.

Akt is a key regulator of numerous cellular phenotypes associated with cancer, including cell survival, proliferation, and metastasis (7). Hyperactivation of Akt due to mutations in the PI3CA, the catalytic subunit of the p110α subunit of phosphoinositide 3-kinase, PTEN loss, INPP4B loss, or HER2 amplification are common features of many tumors (8, 9). The three mammalian Akt isoforms (Akt1, Akt2, and Akt3) are encoded by distinct genes, have high sequence similarity and are activated by near-identical mechanisms (10, 11). The critical role of Akt in modulating cancer cell survival and growth has been well characterized (12). However, the role played by individual Akt isoforms in different molecular subtypes of breast cancer has not been extensively evaluated. In particular, it is not known whether a specific Akt isoform plays a predominant role in TNBC. In the context of breast cancer invasion and metastasis, Akt isoforms have nonredundant roles whereby Akt1 inhibits invasion and metastasis, yet Akt2 promotes these phenotypes both in vitro and in mouse models of breast cancer progression (11–14). Akt3 is arguably the least studied isoform, and its function in breast cancer cell proliferation, survival, and migration is not known. Nevertheless, isoform-specific functions of Akt3 have been evaluated, especially in knockout mice in which the brain size of Akt3 null mice is reduced (15, 16). Akt3 has a putative oncogenic function is supported by the observation that it is overexpressed with high enzymatic activity in ER− breast cancer cells (17). This agrees with the analysis by The Cancer Genome Atlas Project (TCGA) that has reported upregulation of AKT3 expression in 28% of TNBCs (5). The recent identification of somatic mutations of AKT3, including MAGI3–Akt3 and Akt3E17K, in different cancers also points to an important role of this isoform in tumorigenesis (18, 19). However, a causal role for Akt3 in breast cancer initiation and growth has not been examined.

Here, we report that Akt3 is a critical regulator of the growth of TNBCs. Downregulation of Akt3 using short hairpin RNA (shRNA) inhibits tumor spheroid growth in three-dimensional (3D) as well as in xenografts. Akt3 depletion is accompanied by...
robust upregulation of the cell-cycle inhibitor p27. Silencing p27 rescues spheroid growth inhibition mediated by Akt3 depletion, indicating that Akt3 modulates tumor growth, at least in part, via p27. These findings point to a previously underappreciated isoform-selective role for Akt3 in the tumorigenesis of TNBC, and demonstrate that inhibition of Akt3-specific signaling might be exploited for therapeutic purposes.

Materials and Methods

Cell culture

MCF7, MDA-MB-231, MDA-MB-468, T47D, Hs578T, and HEK293T cells were obtained from American Type Culture Collection (ATCC) and maintained in Dulbecco’s Modified Eagle Medium (DMEM; Cellgro) supplemented with 10% FBS (HyClone). SKBR3 and MDA-MB-453 cells obtained from ATCC were grown in RPMI-1640 medium supplemented with 10% FBS. BT-549 cells obtained from ATCC were grown in RPMI-1640 medium supplemented with 10% FBS. SUM-159-PT cells were cultured in Ham’s F12 medium (Cellgro) supplemented with 5% FBS, 1 µg/mL hydrocortisone (Sigma-Aldrich), and 5 µg/mL insulin (Sigma-Aldrich). ZR-75-30 and BT474 cells obtained from ATCC were grown in RPMI-1640 medium (Cambrex) supplemented with 10% FBS and 10 µg/mL insulin. MCF10DCIS.com (20) were grown in DMEM/Ham's F12 medium supplemented with 5% equine serum (Gibco-BRL), 10 µg/mL insulin, 500 ng/mL hydrocortisone (Sigma-Aldrich), 20 ng/mL EGF (R&D Systems), and 100 ng/mL cholecalcitonin (Sigma-Aldrich). All cell lines obtained from the cell banks listed above are tested for authentication and are maintained for fewer than 6 months, and routinely assayed for mycoplasma contamination.

3D cultures

3D cultures were prepared as previously described (21). Briefly, chamber slides were coated with growth factor-reduced Matrigel (BD Biosciences) and allowed to solidify for 30 minutes. About 4,000 MCF10DCIS or MDA-MB-231 cells in assay medium were seeded on coated chamber slides. Assay medium for MCF10DCIS contains DMEM/Ham’s F12 supplemented with 2% equine serum, 10 µg/mL insulin, 500 ng/mL hydrocortisone, 5 ng/mL EGF, 100 ng/mL cholera toxin, 2 µg/mL puromycin, and 2% Matrigel. MDA-MB-231 assay medium contains DMEM supplemented with 2% tet system approved FBS (Clontech) and 5% Matrigel. The assay medium was replaced every 4 days. About 100 ng/mL doxycycline was added every 2 or 3 days.

Antibodies

Anti-Akt1 monoclonal antibody (mAb), anti-Akt2 mAb, anti-Akt3 mAb, anti-phospho-Akt S473 (pAkt) mAb, and anti-p27 mAb were obtained from Cell Signaling Technology. Anti-β-actin mAb was purchased from Sigma-Aldrich. Anti-bromo-deoxyuridine (BrdUrd) mAb was obtained from Roche. Anti-β5 polyclonal antibody was generated in house and has been described previously (22). Horseradish peroxidase (HRP)—conjugated anti-mouse and anti-rabbit immunoglobulin G antibodies were purchased from Chemicon.

RNA interference

For doxycycline-inducible shRNA-mediated knockdown of Akt isoforms, a set of single-stranded oligonucleotides encoding the Akt1, Akt2, and Akt3 target shRNA and its complement were synthesized. The hairpin sequences have been validated previously (11). Akt1, sense, 5'-CCGGGAGTTTGATGCTCATC- GAAGCTGCTGACGCAGCTTGTTATGAACTCTTTTGG-3'; Akt2, sense, 5'-CCGGGCGTTGGAATACATCAAGACCTC- CGAGGCTTTGATGTTACCCACCGCTTTTTG-3'; and Akt3, sense, 5'-CCGGCCAAGTCCGTCTGGTACAATCATCTTTTGGAAGAT- GTAGATGCACAGCATTTTCTTTG-3'. The oligonucleotide sense and antisense pair was annealed and inserted into tet-on plKO. To produce lentiviral supernatants, 293T cells were cotransfected with control or shRNA-containing tet-on plKO vectors, vesicular stomatitis virus G glycoprotein, and psPAX2 for 48 hours. p27 shRNA sequence (sense, 5'-CCGGAAGTCAGGTGCAAGAGGTGCTGACGCAGCTTGTTATGAACTCTTTTGG-3') previously validated (23) was cloned into the tet-on plKO lentiviral expression system as described above. Cells stably expressing doxycycline-inducible shRNA were cultured in medium containing puromycin (0.5–2 µg/mL). Gene knockdown was induced by incubating cells with 100 ng/mL doxycycline for 48 to 72 hours.

Plasmids

For doxycycline-inducible overexpression of Akt3, HA–Akt3/pTRIPZ was constructed. HA–Akt3 cDNA was amplified by PCR from HA–Akt3/pcDNA3. The resulting PCR product was digested with restriction enzymes AgeI and Clai, followed by insertion into pTRIPZ lentiviral vector (Thermo Scientific).

shRNA screen

Screening was performed as described previously (24). Briefly, cells were infected with a library of lentiviral shRNAs directed against 26 human kinases commonly gained and overexpressed in breast cancer. Infected cells were selected for puromycin resistance, and cultured for 6 days. Cell viability/proliferation was assessed using CellTiter-Glo (Promega). Suppression of growth was defined as the capacity for at least two clones of shRNA targeting the same gene to decreased proliferation by ≥30% compared with control.

Xenograft studies

Female nude mice (6–8-week-old) were purchased from Taconic and maintained and treated under specific pathogen-free conditions. All procedures were approved by the Institutional Animal Care and Use Committee at Dana-Farber Cancer Institute (Boston, Massachusetts) and conform to the federal guidelines for the care and maintenance of laboratory animals. The mice were injected subcutaneously with 1 x 10⁶ MCF10DCIS or 2 x 10⁶ MDA-MB-468 cells in media with 50% Matrigel. The mice were randomly divided into control and treatment groups and treated with water supplemented with 1 mg/mL doxycycline and 2% sucrose or standard water supply. Tumor formation was examined every 2 to 3 days for the whole duration of the experiment. One hour before tumor harvesting, BrdUrd was injected intraperitoneally to assess cell proliferation. Tumors were harvested and weighed at the experimental endpoint.
Immunohistochemistry of formalin-fixed paraﬃn-embedded xenograft tumors

Xenograft tumors were deparafﬁnized in xylene and hydrated in a series of ethanol. After heat-induced antigen retrieval in citrate buffer (pH 6), the samples were blocked with donkey serum. Slides were then incubated with primary antibodies for overnight at 4°C. Samples were washed three times with TBS followed by incubation with biotinylated secondary antibodies for 1 hour. The slides were washed and developed using the 3,3′-Diaminobenzidine Metal Enhanced Kit (Vector Labs) and counter-stained with hematoxylin.

Transwell migration assays

A total of 1 × 10⁶ cells in serum-free medium containing 0.1% bovine serum albumin were added to the upper chambers in triplicate. NIH 3T3 cell-conditioned medium was added to the lower chambers. After 2 to 16 hours of incubation at 37°C, nonmigrated cells on Transwell ﬁlters (8 μm pore size; Corn-ing) were removed. Cells that had migrated to the bottom of the ﬁlters were ﬁxed and stained using the Hema-3 stain set (Protocol).

Cell viability assays

MDA-MB-231 and SKBR3 cells were seeded 24 hours before inhibitor treatment into 96-well plates at density of 2,000 to 4,000 cells per well in 100 μL medium. Cell viability was measured 72 hours after inhibitor treatment using the water soluble tetrazolium salt (WST)-1 assay (Clontech) according to the manufacturer’s protocol.

Quantitative real-time PCR

Total RNA was isolated with TRIzol (Invitrogen) according to the manufacturer’s protocol. Reverse transcription was performed using random hexamers and multiscribe reverse transcriptase (Applied Biosystems). Quantitative real-time PCR was performed using an ABI Prism 7700 sequence detector. Akt isoform–speciﬁc primers have been validated previously (25). Akt1 primer: sense, 5′-CAACGCTTATCACACCAAG-3′; Akt2 primer: sense, 5′-GCAAGGCAAGGCTTAAGG-3′; and Akt3 primer: sense, 5′-GAAGGAGAGATGAAAAAGT- CCA-3′. PCR reactions were carried out in triplicate. Quantitation of mRNA expression was calculated by the dCT method with glyceraldehyde-3-phosphate dehydrogenase as the reference gene.

Immunobots

Cells were washed with PBS at 4°C and lysed in radioimmuno precipitation assay buffer (1% NP-40, 0.5% sodium deoxycholate, 1% SDS, 150 mmol/L NaCl, 50 mmol/L Tris–HCl (pH 7.5), protease inhibitor cocktail, 50 mmol/L, pyrophosphate, and 20 mmol/L, sodium ﬂuoride) for 15 minutes at 4°C. Cell extracts were precleared by centrifugation at 13,000 rpm for 10 minutes at 4°C and protein concentration was measured with Bio-Rad protein assay reagent using a Beckman Coulter DU-800 machine. Lysates were then resolved on 10% acrylamide gels by SDS–PAGE and transferred electrophoretically to nitrocellulose membrane (Bio-Rad) at 100 V for 60 minutes. The blots were blocked in Tris–buffered saline (TBST) (10 mmol/L, pH 8, 150 mmol/L NaCl and 0.2% Tween 20) containing 5% (w/v) nonfat dry milk for 30 minutes, and then incubated with the speciﬁc primary antibody diluted in blocking buffer at 4°C overnight. Membranes were washed three times in TRIST, and incubated with HRPconjugated secondary antibody for 1 hour at room temperature. Membranes were washed three times and developed using enhanced chemiluminescence substrate (Pierce).

Survival analyses in clinical cohorts of TNBC

To determine the association of AKT3 mRNA expression with patient survival, we used two publicly available clinically annotated breast cancer gene expression datasets. The first is a published gene expression microarray (GEM) meta-dataset that integrates gene expression and survival data from a total of 19 published studies, including a total of 2,731 patients, as described in ref. 26. Of note, 527 of these patients were molecularly subtyped using the three-gene model of (27) as ER-/HER2+. Given that true PR expression is not observed in ER− breast cancer (28), this group is representative of TNBC. To assess the association of AKT3 expression with survival among these patients with ER-/HER2+ breast cancer, we performed a Cox proportional hazards analysis. To assess the association of a binary AKT3 expression score with survival, we thresholded the AKT3 expression at the TNBC population median and plotted Kaplan–Meier curves in AKT3-high expressing versus AKT3-low expressing tumors. We assessed the significance in difference between survival curves by performing a log-rank test. We performed a similar set of analyses on the METABRIC dataset, which is composed of a total of approximately 2,000 breast cancer cases with clinical follow-up, as described in ref. 29. Pathologic data for ER, PR, and HER2 expression were available for this cohort, and based on these data we identiﬁed 319 patients with TNBC. The METABRIC dataset contained four probes for the AKT3 mRNA. For each probe, we performed Cox proportional hazards analysis to overall survival. To assess the association of a binary AKT3 expression score with survival, we computed the mean AKT3 expression for each patient and thresholded the mean AKT3 expression score at the TNBC population median. We plotted Kaplan–Meier curves in AKT3-high expressing versus AKT3-low expressing tumors and performed a log-rank test to assess differences in the curves.

Results

Overexpression of Akt3 in TNBC

To identify genes that are necessary for growth of TNBC, we screened a panel of 17 commonly studied breast cancer lines as well as two triple-negative nontumorigenic, immortalized mammary epithelial lines (MCF-10A and MCF-12A) with a library of lentiviral shRNAs targeting 26 protein kinases ampliﬁed in breast tumors. Akt3 was found to be one candidate gene that was preferentially required for TNBC growth. In 10 of 10 TNBC lines tested (including both mesenchymal and basal-like subtypes), Akt3 depletion leads to growth inhibition (Fig. 1A). In contrast, proliferation is inhibited in only 3 of 9 luminal cancer lines transduced with Akt3 shRNA (P for difference in proportions = 0.009). To investigate whether there is a correlation between Akt3 expression and breast tumor subtypes, we
analyzed a dataset of breast cancer from TCGA (n = 825). Samples with Akt3 amplification have an overrepresentation in the TNBC subtype (14%) and an underrepresentation in luminal tumors (3%; Fig. 1B). In addition, whereas Akt3 mRNA is upregulated in 2% luminal breast tumors, its expression is significantly higher in 21% of TNBCs. To determine whether this is also observed in breast cancer cell lines, we quantified mRNA levels for individual Akt isoforms. Although all cell lines tested express Akt1 and Akt2, Akt3 is exclusively expressed in TNBC lines (Fig. 1C). Correspondingly, 5 of 5 triple-negative lines express Akt3 at the protein level as observed by immunoblot analysis, whereas only one of the tested luminal lines shows detectable Akt3 expression (T47D; Fig. 1D).

To evaluate the association of Akt3 mRNA expression with patient survival in TNBC, we used two of the largest sets of publicly available clinically annotated breast cancer gene expression data. The first is a published GEM meta-dataset that integrates gene expression and survival data from a total of 19 published studies, including a total of 2,731 patients, as described previously (26). The second analysis was performed on the full METABRIC dataset, which is composed of a total of approximately 2,000 breast cancer cases with clinical follow-up, as described previously (29). Analysis of both datasets provides no evidence to suggest that AKT3 mRNA expression levels are an important predictor of survival in TNBC (Supplementary Fig. S1). However, mRNA expression levels may
show poor correlation with levels of activated Akt3, and thus may be poor markers of pathway activation. Thus, to definitely determine the association of Akt3 signaling with patient survival, it will be important to perform analyses assessing the relationship between phosphorylated/activated Akt3 and patient survival on large clinical cohorts. These data are currently unavailable from public databases of clinically annotated molecular profiling data in breast cancer.

Akt3 depletion potently inhibits breast tumor spheroid growth and sensitizes TNBC to an Akt inhibitor

To explore the function of Akt3 in TNBC, we generated a panel of breast cancer lines with tet-on doxycycline-inducible Akt1, Akt2, or Akt3 shRNA. Upon doxycycline administration, Akt isoforms are depleted specifically and quantitatively (Fig. 2A). We investigated the consequence of Akt3 silencing on tumor spheroid growth using a 3D culture system in vitro that more accurately recapitulates phenotypes that govern tumor growth in vivo. Depletion of Akt3 in MDA-MB-231 cells potently inhibits spheroid growth (Fig. 2B), resulting in a 57% reduction of spheroid size (Fig. 2C). In contrast, the effect of Akt1 or Akt2 depletion on spheroid growth is much more modest. A 26% reduction in spheroid size is observed in Akt2-depleted cells, whereas there is no significant change in spheroid size when Akt1 is silenced. Knockdown of Akt3 in another triple-negative line, MCF10DCIS, cloned from a xenograft lesion formed by premalignant MCF-10AT cells and has the oncogenic mutation H1047R in the p110α catalytic subunit (PIK3CA; ref. 30), has similar effect on the inhibition of spheroid growth (56% reduction; Fig. 2D). Conversely, depletion of Akt1 or Akt2 has minimal effect on the growth of spheroids. These data suggest that Akt3 has a selective role in promoting tumor spheroid growth of TNBCs.

Data from a recent study have demonstrated that the majority of TNBC are resistant to the pan-Akt inhibitor GDC-0068 (31). Because most of the TNBC lines tested express...
Akt3, we next determined whether Akt3 loss in TNBC might result in increased sensitivity to Akt inhibition. Although MDA-MB-231 cells are resistant to the ATP-competitive inhibitor GSK690693 (IC\textsubscript{50} 24.2 μmol/L), loss of Akt3 results in a 6-fold decrease in IC\textsubscript{50} (3.8 μmol/L; P < 0.0001; Fig. 2E). Similarly, Akt3 depletion in MCF10DCIS cells leads to a 28-fold decrease in IC\textsubscript{50} (0.54 vs. 15.4 μmol/L in control cells; P < 0.0001; data not shown). To further determine the role of Akt3 in drug sensitivity, we overexpressed Akt3 in a luminal breast cancer line, SKBR3, which does not express this Akt isoform. Overexpression of Akt3 results in a 2.7-fold increase in IC\textsubscript{50} for GSK690693 compared with control cells (13.4 vs. 5 μmol/L in control cells; P < 0.05; Fig. 2F). Together, these data indicate that Akt3 plays an important role in conferring resistance to pan-Akt inhibitors in TNBCs.

p27 is a key regulator of cell-cycle progression. Studies have shown that Akt inhibits p27 expression via the transcription factor forkhead box O (32). Moreover, phosphorylation by Akt has been shown to promote the proteasomal degradation of p27 (33), thereby regulating its expression at both the transcriptional and posttranslational level. However, it is not known whether p27 is regulated redundantly by all Akt isoforms, or whether specificity exists. In this context, in MCF10DCIS cells Akt1 silencing results in increased p27 protein expression (Fig. 3A), whereas p27 levels are diminished upon Akt2 silencing. Interestingly, p27 is significantly elevated in Akt3-depleted cells. Similar results are observed in two other TNBC lines, MDA-MB-231 and MDA-MB-468 (Fig. 3A). To determine whether Akt3 promotes tumor cell proliferation by modulating p27 expression levels, we performed a rescue experiment by silencing p27. As shown in Fig. 3B, approximately 50% of p27 is depleted by specific shRNA. Downregulation of p27 alone has minimal effect on 3D spheroid growth (Fig. 3C). In contrast, Akt3 shRNA-mediated spheroid growth inhibition is completely rescued by p27 silencing, indicating that the effect of Akt3 on tumor spheroid growth is mediated, at least in part, by p27.

**Role of Akt isoforms in modulating invasiveness of tumor spheroids**

We and others have shown that Akt1 and Akt2 have opposing functions in regulating breast cancer cell invasion and metastasis (12). However, a functional role for Akt3 in modulating cancer cell migration has not been evaluated. To assess chemotactic cell migration, Transwell migration assays were performed. In three TNBC lines (MCF10DCIS, MDA-MB-468, and BT-549), Akt1 and Akt2 silencing leads to increased and decreased cell migration, respectively (Fig. 4A), in agreement with published studies. A statistically significant but modest enhancement of migration is observed upon Akt3 silencing in all three lines. Furthermore, Akt1 silencing promotes an abnormal branching morphology with cells protruding into Matrigel (Fig. 4B). In contrast, spheroids remain round and uniform when Akt2 or Akt3 is depleted. These results indicate

---

**Figure 3.** p27 is a downstream effector of Akt3 in regulating tumor spheroid growth. A, MCF10DCIS and MDA-MB-468 cells expressing tet-on Akt isoform shRNA were treated with doxycycline (Dox; 100 ng/mL) for 3 days, followed by immunoblot analysis. MDA-MB-231 cells were infected with Akt isoform shRNA/pLKO lentiviral vectors for 3 days, followed by immunoblot analysis. B, MCF10DCIS cells were infected with tet-on p27 shRNA lentiviral vector. Three days after doxycycline (100 ng/mL) treatment, cell lysates were immunoblotted with anti-p27 and anti-p85. C, MCF10DCIS cells expressing tet-on p27 shRNA and/or Akt3 shRNA were seeded to 3D culture for 24 hours, followed by treatment with dox (100 ng/mL) for an additional 7 days. Spheroid size (n = 100) was quantified. **, P < 0.01, ***, P < 0.001.
that Akt3 plays a critical role in modulating tumor spheroid growth in the absence of significant effects on breast cancer cell invasive migration.

**Akt3 downregulation attenuates breast tumor growth in vivo**

Next, we evaluated the contribution of Akt3 to tumorigenesis in vivo. Because Akt3 selectively inhibits tumor spheroid growth of TNBC lines, MDA-MB-468 cells stably expressing tet-on Akt1, Akt2, and Akt3 shRNA were injected subcutaneously into nude mice. When Akt3 is depleted by inducing shRNA expression via doxycycline in drinking water, there is a significant reduction in tumor growth (Fig. 5A). In striking contrast, silencing Akt1 or Akt2 has no significant effect on tumor growth. To confirm the knockdown of Akt isoforms and to assess their effect on cell proliferation as well as p27 expression, immunohistochemistry (IHC) was performed on xenografts harvested at the end of the study. Akt protein levels are dramatically reduced in doxycycline-treated tumors when compared with their vehicle-treated counterparts (Fig. 5B). Depletion of Akt3, but not Akt1 or Akt2, is concomitant with a significant reduction in BrdUrd staining, consistent with the notion that Akt3 plays a critical role in tumor cell proliferation in vivo. Similar to what is observed with the in vitro analysis, depletion of Akt3, but not Akt1 or Akt2, leads to a marked elevation of p27 expression. Interestingly, silencing of either Akt1 or Akt3 markedly reduces tumor growth in a distinct triple-negative line, MCF10DCIS (Fig. 5C). The more marked effect of Akt1 on MCF10DCIS tumor growth in vivo compared with in vitro could be due to paracrine function of Akt1 in the tumor-associated stroma and microenvironment (12). Doxycycline itself has no effect on tumor growth because the growth of tumors containing empty vector in the absence of doxycycline is indistinguishable from doxycycline-treated tumors (Fig. 5C). Similar to what is observed in MDA-MB-468 cells, silencing Akt3, but not Akt1 or Akt2, leads to robust upregulation of p27 expression (Fig. 5D). Taken together, these data demonstrate that TNBC growth can be inhibited by silencing Akt3 alone.

**Discussion**

TNBCs are especially aggressive and have a relatively poor prognosis compared with other breast tumor subtypes. In the present study, we set out to identify molecular targets of TNBC.
Akt3 in Triple-Negative Breast Cancer

Figure 5. Akt3 depletion attenuates tumor growth in vivo. A, doxycycline (Dox; 1 mg/mL) was administered to mice in drinking water started 1 day after subcutaneous injection of MDA-MB-468 cells expressing Akt isoform shRNA (n = 10). Tumor volume was measured on days 22, 31, 40, 48, and 64 after injection. Bar graphs, tumor xenograft weights 64 days after injection. **P < 0.001. B, Akt isoforms, BrdUrd, and p27 IHC staining for xenografts in A, C, MCF10DCIS cells expressing Akt isoform shRNA or empty vector were injected subcutaneously into nude mice (n = 10). Doxycycline (1 mg/mL) was administered to mice in drinking water started 1 day after injection. Plots depict tumor volumes measured on days 11, 14, 18, 22, and 26 after injection. D, Akt isoforms and p27 IHC staining for xenografts in C.

with therapeutic potential using an RNAi functional genetic screen. We find that Akt3 silencing preferentially inhibits the proliferation of TNBC cell lines both in vitro and in xenografts. Consistent with this, Akt3 is overexpressed in 21% and 2% of triple-negative and luminal breast tumors, respectively. To determine the contribution of individual Akt isoforms in triple-negative tumor growth, we used an inducible shRNA strategy. Silencing Akt3, but not Akt1 or Akt2, dramatically reduces tumor spheroid growth in 3D. The selective effect of Akt3 in triple-negative tumor is noteworthy because it has been largely assumed that Akt isoforms play redundant roles in regulating tumor proliferation and growth. Furthermore, an isoform-specific function of Akt3 in any cancer context has not yet demonstrated. In breast cancer, published studies have focused on the opposing functions of Akt1 and Akt2 on cell migration and invasion. Several downstream Akt targets have been shown to contribute to the differential functions of these two isoforms in motility, including palladin, nuclear factor of activated T cells, tuberous sclerosis complex 2, and β1 integrins (34–37). In this study, we find that although Akt3 is required for TNBC proliferation and tumor growth, unlike Akt1 it does not promote an invasive phenotype. These findings have significant implications for targeted therapeutics, because currently all Akt small molecule inhibitors in phase I and II clinical trials are not isoform selective. One prediction is that pan Akt inhibitors could have undesired clinical effects by actually promoting invasion and even metastasis, because Akt1 has been shown to have both antiinvasive and antimetastatic activity in vivo. In contrast, targeting Akt3 exclusively in TNBCs may have the advantage of inhibiting tumor growth without any significant impact on metastatic dissemination. Furthermore, due to the critical roles of Akt isoforms in tissue homeostasis, pan-Akt inhibitors are expected to be dose limiting. Instead, we would argue that isoform-specific
inhibitors, including Akt3-specific drugs, would likely have less associated toxicity and provide a better therapeutic window. Further support for the need to develop Akt3-specific inhibitors for the therapeutic targeting of TNBC tumors comes from a recent study on the sensitivities of different breast cancer lines to the pan-Akt inhibitor GDC-0068 (31). Of all luminal lines tested in this study, 5 of 6 lines are sensitive to GDC-0068 with an IC50 < 2 μmol/L. In agreement with our expression analysis, most of these lines have undetectable levels of Akt3. In contrast, 5 of 5 TNBC lines tested express Akt3, and 3 of them are insensitive to GDC-0068 (MDA-MB-468, MDA-MB-231, and MCF10A; IC50 > 10 μmol/L; BT-549; IC50 5.6 μmol/L; Hs578T IC50 2.2 μmol/L). Consistent with this, we show that MDA-MB-231 and MCF10DCIS cells are resistant to the pan-Akt inhibitor GSK690693. Importantly, Akt3 depletion in both lines resulted in robust sensitization to the drug, suggesting a critical role of Akt3 in conferring resistance to pan-Akt inhibitor in TNBCs. It will be interesting to determine whether there is a correlation between Akt3 expression and sensitivity to pan-Akt inhibitors in clinical samples.

On the basis of the gene expression signatures, seven distinct subtypes of TNBC have been proposed, with a classification that comprises two basal-like, immunomodulatory, mesenchymal, mesenchymal stem-like (MSL), and luminal androgen receptor subtypes (38). Recent reports indicated that different subtypes of TNBCs may respond differently to targeted and chemotherapies (39). Our data point to a distinct function of Akt3 in MDA-MB-468 and MDA-MB-231 breast cancer lines, which belong to the basal-like 1 and MSL subtype, respectively. Future studies warrant evaluating the impact of Akt isoform-specific signaling in the various proposed TNBC subtypes.

Our study has also uncovered distinct roles of Akt isoforms in the regulation of p27. It has been shown that Akt is a negative regulator of p27. Here, we demonstrate that Akt2, in contrast with Akt1, positively regulates p27 expression. Surprisingly, silencing Akt3 results in a robust elevation of p27 expression concomitant with inhibition of the growth of TNBC lines in vitro as well as in xenografts. Using an shRNA rescue strategy, we show that p27 plays a critical function in the regulation of tumor spheroid growth mediated by Akt3. These findings not only lend further support to the notion of nonredundant functions of Akt isoforms at the molecular level, they also suggest the potential use of p27 as a biomarker of Akt3 activity.

Depletion of Akt3 alone inhibits MCF10DCIS and MDA-MB-468 xenograft tumor growth. Interestingly, although Akt1 has minimal effect in modulating spheroid growth, silencing Akt1 in MCF10DCIS in xenografts leads to a reduction of tumor growth comparable with that observed with Akt3 depletion. This is likely due to the functional importance of Akt1 signaling in the tumor-associated stroma because this isoform plays an important role in promoting VEGF-mediated angiogenesis (40). Whether angiogenesis contributes to the effect of Akt1 on MCF10DCIS growth in our model remains to be determined.

In conclusion, our studies demonstrate that targeting Akt3 and downstream signaling may be an effective approach to inhibit growth of TNBC. Because Akt3-specific inhibitors have yet to be developed, we propose that the development of such inhibitors could constitute the basis for Akt3 as a novel target for single agent or combination therapy.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: Y.R. Chin, K. Polyak, A. Toker
Development of methodology: Y.R. Chin
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Y.R. Chin, T. Yoshida, A. Murausky
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Y.R. Chin, T. Yoshida, A. Murausky, A. H. Beck, K. Polyak, A. Toker
Writing, review, and/or revision of the manuscript: Y.R. Chin, A. Murausky, A. H. Beck, K. Polyak, A. Toker
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A. H. Beck, A. Toker
Study supervision: Y.R. Chin, K. Polyak, A. Toker

Acknowledgments
The authors thank the confocal imaging core and histology core at BIDMC for their technical support with IHC; Casey Stottrup for technical assistance with 3D cultures, migration assays, and immunohistochemistry; Evan Lien for providing pTRIPZ-Akt3 plasmid; and members of the Toker laboratory for discussions.

Grant Support
This study was supported in part by grants from the NIH (K99CA157945 to Y.R. Chin, CA092644 and T32 CA081156 to A. Toker), the Susan G. Komen Foundation (K. Polyak), from a sponsored research grant from Incyte/El Lilly (A. Toker and Y.R. Chin), and from an award from the Klarman Family Foundation (A.H. Beck).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 2, 2013; revised November 4, 2013; accepted November 20, 2013; published OnlineFirst December 12, 2013.

References
Akt3 in Triple-Negative Breast Cancer

Targeting Akt3 Signaling in Triple-Negative Breast Cancer

Y. Rebecca Chin, Taku Yoshida, Andriy Marusyk, et al.


Updated version
Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-13-2175

Supplementary Material
Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2013/12/12/0008-5472.CAN-13-2175.DC1

Cited articles
This article cites 40 articles, 18 of which you can access for free at: http://cancerres.aacrjournals.org/content/74/3/964.full#ref-list-1

Citing articles
This article has been cited by 8 HighWire-hosted articles. Access the articles at: http://cancerres.aacrjournals.org/content/74/3/964.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.